ArticleThe Journal of urology2020
Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014.
Article in The Journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Temporal trends in serum testosterone and luteinizing hormone levels indicate an ongoing resetting of hypothalamic-pituitary-gonadal function in healthy men: a systematic review.Journal of endocrinological investigation · 2025Pooled it
- Article
- Alternatives to serum testing for transdermal testosterone monitoring: a review of clinical data and correlation with clinical response.Frontiers in reproductive health · 2026Article
- Preoperative testosterone replacement therapy: a potential risk-factor for complications and reoperation after rotator cuff repair.JSES international · 2026Article
- Review
- Testosterone Concentration and Incident Depression in Older Men: A Longitudinal Cohort Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy.Transfusion · 2024Article
- Trends in testosterone prescription during the release of society guidelines.International journal of impotence research · 2024Article
- Oncologic Outcomes of Testosterone Therapy for Men on Active Surveillance for Prostate Cancer: A Population-based Analysis.European urology open science · 2024Article
- Young Adults' Understanding of Modifiable Risk Factors of Infertility.Women's health reports (New Rochelle, N.Y.) · 2024Article
- Article
- Article
- Trends in testosterone prescription amongst medical specialties: a 5-year CMS data analysis.International journal of impotence research · 2023Article
- Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.Clinical endocrinology · 2022Article
- Vasectomy reversal outcomes in men after testosterone therapy.Scientific reports · 2022Article
- Testosterone replacement therapy in the era of telemedicine.International journal of impotence research · 2022Review
- Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015.Cancer epidemiology · 2022Article
- The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.Cancer causes & control : CCC · 2021Article
- Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Unmasking Masculinity: Biological, Behavioral, and Social Determinants of Testosterone Deficiency in U.S. Men, 2011-2023.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
purposeWe explored the Medicare database (1999 to 2014) to provide a comprehensive assessment of testosterone therapy patterns in the older U.S. male population. MATERIALS AND
methodsWe estimated annual age-standardized incidence (new users) and prevalence (existing users) of testosterone therapy according to demographic characteristics, comorbidities and potential indications.
resultsThere were 392,698 incident testosterone therapy users during 88 million person-years. Testosterone therapy users were predominantly younger, white nonHispanic, and located in South and West U.S. Census regions. On average testosterone therapy use increased dramatically during 2007 to 2014 (average annual percent change 15.5%), despite a decrease in 2014. In 2014 the most common recorded potential indications for any testosterone therapy were hypogonadism (48%), fatigue (18%), erectile dysfunction (15%), depression (4%) and psychosexual dysfunction (1%). Laboratory tests to measure circulating testosterone concentrations for testosterone therapy were infrequent with 35% having had at least 1 testosterone test in the 120 days preceding testosterone therapy, 4% the recommended 2 pre-testosterone therapy tests, and 16% at least 1 pre-testosterone therapy test and at least 1 post-testosterone therapy test.
conclusionsTestosterone therapy remains common in the older U.S. male population, despite a recent decrease. Although testosterone therapy prescriptions are predominantly for hypogonadism, a substantial proportion appear to be for less specific conditions. Testosterone tests among men prescribed testosterone therapy appear to be infrequent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.